We analyzed the long-term outcomes of 1021 patients with acute lymphoblastic leukemia (ALL), enrolled in four successive clinical trials (ALL811, ALL841, ALL874 and ALL911) between 1981 and 1993. All patients received risk-adopted therapy according to leukocyte count and age at the time of diagnosis. The median follow-up durations of the four studies were 17.8 years in ALL811, 15.5 years in ALL841, 11.9 years in ALL874 and 15.8 years in ALL911. Patients' event-free survival (EFS) and overall survival (OS) rates at 12 years were 41.0 and 54.3% in ALL811, 50.2 and 60.2% in ALL841, 57.3 and 64.7% in ALL874, and 63.4 and 71.7% in ALL911, respectively. Thus, cure can become a reality for about 70% of children with ALL. There is, however, still a significant difference in survival outcomes according to risk group. Late effects were observed in 70 patients out of 834 (8.4%); hepatitis and short stature were most commonly reported. Reduction of late adverse effects for all patients and development of new treatment strategies for very-high-risk patients are major issues for upcoming trials to address.
Introduction
The therapeutic experience of acute lymphoblastic leukemia (ALL) is one of the true success stories of modern clinical oncology. Incremental advances in treatment success span a 50-year period during which ALL has progressed from a uniformly fatal disease to an illness with an overall cure rate of 75-85%. [1] [2] [3] [4] This extraordinary progress has resulted from advances in treatment beginning with the identification of effective single-agent chemotherapy in the late 1940s, followed by development of combination and maintenance chemotherapy and introduction of central nervous system (CNS) preventive therapy in the 1960s. Tailoring therapy according to risk factors, followed by more intensified chemotherapy with improvements in supportive care, further increased the cure rate from the 1980s through early 1990s. On the other hand, late adverse effects have become an important issue disturbing the quality of life of long-term survivors.
For over 25 years, we have conducted successive clinical trials (ALL811, ALL841, ALL874, ALL911, ALL941 and ALL2000) on children with ALL, and have achieved consistent improvement in treatment outcomes. [5] [6] [7] [8] [9] [10] [11] [12] Here, we show longterm outcomes of patients treated from the early 1980s through the mid 1990s (ALL811, ALL841, ALL874 and ALL911), and also discuss late adverse effects.
Materials and methods

Patients
A total of 1021 untreated ALL patients below 18 years of age were registered to participate in a series of Japanese Childhood Cancer and Leukemia Study Group (JCCLSG) trials (ALL811, ALL841, ALL874 and ALL911) conducted in 21 hospitals, all of which were members of the JCCLSG. Written informed consent was provided by patients or legal guardians before treatment. ALL diagnoses were based on cytomorphology (FAB criteria, L1/L2) and cytochemistry when^25% lymphoblastic cells were present in bone marrow samples. Flow-cytometric immunophenotyping was performed only for patients in the ALL911 studies at the central laboratory (Aichi Medical University), but was not mandatory. Based on age and leukocyte count at diagnosis, 6 patients were stratified into one of the following groups: low-risk (LR), intermediate-risk (IR) or high-risk (HR). In ALL811, patients in the LR or IR group were defined as the standard-risk (SR) group. 7 Of HR patients in ALL911, cases with initial leukocyte count greater than 100 Â 10 9 /l were further stratified into a 'high-high-risk' (HHR) group (Table 1) .
Treatment protocols
Details of treatment protocols have been described in earlier publications. [7] [8] [9] [10] An outline of treatment regimens in the protocols and detailed therapy schedules, including drug dosage, are provided in Tables 2 and 3, respectively. ALL811. The main aim of the S811 protocol was a randomized control study of two different maintenance chemotherapies. 7 SR patients received a two-drug (VP) induction therapy consisting of vincristine (VCR) and prednisolone (PSL). After achieving complete remission, they were randomized to either arm-A, consisting of intermittent cyclic administration of four drugs (VPM-M regimen), VCR, PSL, 6-mercaptopurine (6MP) and intermediate-dose methotrexate (MTX), or arm-B, consisting of continuous low-dose MTX and 6MP combined with VP pulse. HR patients were randomly assigned to the H811A or H811B arms to compare the high-dose (HD) MTX and cranial irradiation (CRT) regimens for CNS prophylaxis. In the H811A arm, doxorubicin (DOX) was employed as consolidation therapy.
ALL841.
The main aim of this study was improvement of induction therapy. Patients in the LR group were assigned randomly to the two-drug induction regimen (VP) in the L841A arm or a three-drug regimen (VP plus L-asparaginase,LASP) in the L841B arm. The maintenance therapy consisted of the VPM-ML regimen in L841A or the VPM-ML regimen incorporating LASP in L841B. In HR patients, the efficacy of addition of cyclophosphamide (CPM) in induction and maintenance therapy was studied in the H851A and H851B arms. Starting in 1985, the treatment lasted 3 years after the point of achieving complete remission for all patients.
ALL874. The primary aim of this study was to clarify whether CNS-protective chemotherapy without CRT for treatment of non-HR patients could be accepted without compromising outcomes delivered by conventional CRT regimens. LR and IR patients were assigned randomly to the conventional CRT regimen (L874A and I874A) and the HDMTX regimen without CRT (L874B and I874B). In the HR group, the consolidation regimen of intermediate-dose CPM and cytarabine (Ara-C) (CCM regimen) was compared with the regimen of high-dose CPM and Ara-C (CC regimen). In addition, reinduction therapy (VPLA) was newly employed at months 5 and 12 of therapy. The duration of treatment was 3 years for all patients, as in the ALL841 study.
ALL911. The primary aim of this study was to improve HR patient outcomes. For this, we further stratified HR patients into two groups of HR and HHR, with the latter group receiving more intensified chemotherapy. For this study, a non-randomized, single-arm study was selected because of the small number of patients per subset. The four-drug regimen (VPLA/ VPLA 0 ) was used as an induction therapy for all patients, and a tetrahydropyranyl derivative of DOX (pirarubicin, THP) was used instead of DOX as the VPLA 0 regimen for LR and IR patients. The IR, HR and HHR groups received the same consolidation (CCM) and reinduction therapy (VLPA 0 ). For CNS prophylaxis, CRT was omitted for the LR and IR patients. The duration of treatment was 2 years for the LR group and 3 years for the other three groups.
Late effects
A set of written questions on late adverse effects on patients treated with one of the four protocols (ALL811, ALL841, ALL874 and ALL911) was sent to all participating institutes in Table 2 Outlines of JCCLSG protocols for childhood ALL Anthracycline (DOX/THP) was omitted in the second and third years. 
Statistical analysis
Final statistical analyses of ALL911 patients were based on data obtained in June 2008, while those of subjects in the ALL811, ALL841 and ALL874 studies used data obtained in June 2001, when the final survey on outcomes was taken. Survival curves were prepared by the Kaplan-Meier method and a log-rank test was used to detect significant differences between groups. Overall survival (OS) was defined as the time between disease diagnosis and death, and event-free survival (EFS) was defined as the time to first occurrence of induction failure, relapse at any site, death or secondary malignant neoplasm. For patients who experienced no events, EFS was the time to the most recent follow-up. CNS relapse-free survival and bone marrow relapse-free survival were measured from the end of induction and excluded patients who failed to achieve complete remission. The SPSS statistical analysis software (SPSS 12.0J, Japan Inc., Tokyo, Japan) was used for all computations.
Results
Survival outcomes
Long-term survival curves for patients over the four ALL studies are presented in Figure 1 . The median follow-up duration of the four studies was as follows: 17.8 years (range 3. 
Treatment outcomes
Treatment outcomes for the four ALL studies are shown in Table 4 and survival outcomes at 5-year intervals according to treatment protocol and presenting features are shown in Tables 5a-5d.
ALL811.
A total of 230 children were enrolled in the ALL811 study, of which 207 patients were evaluable. Ages ranged from 
CNS prophylaxis See Table 6 Maintenance phase VPM-M Vincristine IV 2 mg/m Abbreviations: ALL, acute lymphoblastic leukemia; Ara-C, cytarabine; HDMTX, high-dose methotrexate; IV, intravenous; JCCLSG, Japanese Childhood Cancer and Leukemia Study Group.
Long-term outcomes of children with acute lymphoblastic leukemia M Tsurusawa et al 0.5 to 15.8 years, with a median of 4.5. In the SR group, the outcome of the S811A study was significantly superior to that of the S811B study. For the HR group, the H811B protocol was closed in 1982 because interim analysis showed an unexpectedly low remission induction rate (16/20, 80%). However, results of long-term outcomes showed that H811B patients seemed to have a better outcome than H811A patients, although the difference did not reach a statistically significant level. Unfavorable prognostic features included NCI high-risk (age o1 or 410 years, with WBC count 450 Â 10 9 /l), 13 high WBC counts (^50 Â 10 9 /l), older age (410 years) and female gender, in descending order (Table 5a ). Two S811A patients developed secondary cancers (one thyroid cancer and one rhabdoid tumor).
ALL841.
A total of 237 children were enrolled in the ALL841 study, with 220 evaluable patients. Ages ranged from 0.4 to 15.7 years, with a median of 5.0. EFS for L841B was significantly higher than that for L841A. Although I841B patients received the same regimen as those in L841B, they showed a significantly lower EFS rate. In HR protocols, there was no significant difference between H851A and H851B. Unfavorable prognostic features included NCI high-risk, older age (410 years) and high Long-term outcomes of children with acute lymphoblastic leukemia M Tsurusawa et al WBC counts (^50 Â 10 9 /l), in descending order (Table 5b) . One HR851A patient developed acute myeloblastic leukemia with t(8; 21).
ALL874.
A total of 389 children were enrolled in the ALL841 study, including 371 evaluable patients. Ages ranged from 0.9 to 16.7 years, with a median of 5.1. For the LR and IR groups, Table 5a Survival outcomes according to treatment protocols and presenting features in patients treated in ALL811 10.0 ± 6.7 10.0 ± 6.7 10.0 ± 6.7 10.0 ± 6.7 35.0 ± 10.7 25.0 ± 9.7 25.0 ± 9.7 25.0 ± 9.7
Abbreviation: ALL, acute lymphoblastic leukemia. Abbreviation: ALL, acute lymphoblastic leukemia.
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Long-term outcomes of children with acute lymphoblastic leukemia M Tsurusawa et al there was no significant difference in outcome between protocols. Conversely, in the HR group, H874A patients showed significantly better outcomes than those of H874B. Unfavorable prognostic features included older age (410 years), NCI high-risk and very high WBC counts (^100 Â 10 9 /l), in descending order (Table 5c ). One LR874A patient developed a 
Long-term outcomes of children with acute lymphoblastic leukemia M Tsurusawa et al hepatocarcinoma and one further I874A patient developed a malignant fibrous histocytoma.
ALL911.
A total of 230 children were enrolled in the ALL911 study, of which 223 patients were evaluable. Ages ranged from 0.7 to 15.8 years, with a median of 5.0. In this study, HHR patient outcome was extremely poor compared with that of HR patients. On the other hand, HR group outcomes compared favorably to those of both LR and IR groups. Unfavorable prognostic features included NCI high-risk, older age (410 years) and very high WBC counts (^100 Â 10 9 /l), in descending order (Table 5d ). One HHR911 patient developed myelodysplatic syndrome and one IR911 patient developed chronic myelogenous leukemia. Table 6 shows CNS relapse-free survival by the CNS prophylaxis regimen. In our four studies, more than half of the patients received prophylactic CRT and proportion of the patients in each study is shown in Table 2 . From the three protocols including L874, I841 and I874, two regimens with or without CRT were compared with respect to their ability to prevent CNS leukemia and to improve the overall ALL outcome. The CRT regimens seem to be associated with better CNS-free survival outcome than the HDMTX regimen. However, the difference was significant in only I874 but not other studies (L874 and I841), and no significant difference in systemic survival rates was observed between the two CNS regimens in either risk group. The CNS remission rate of patients treated with the I911 protocol was significantly higher than that of patients given the HDMTX regimen in the I874B protocol (P ¼ 0.0127), and was comparable to that of patients given the CRT regimen in the I874A protocol. In HR groups, HDMTX regimens without CRT (H851A/B) showed very poor CNS-free survival outcomes.
Extramedullary relapse
The incidence of isolated testicular relapse was very different between maintenance regimens. In the randomized study of SR patients in ALL811, only one of 36 (2.8%) males who received an intermittent cyclic regimen of MTX and 6MP (S811A) developed testicular relapse, in contrast to seven of 31 (22.6%) males receiving continuous administration of low-dose MTX and 6MP for maintenance chemotherapy (S811B). In addition, from the 841 protocol, only seven additional testicular relapses were seen for 497 males (Table 4) .
Late effects
Questionnaire results about late adverse effects in the four studies (ALL811, ALL841, ALL874 and ALL911) were obtained from 521 of 640 (81.4%) living patients and from 313 of 381 (82.1%) deceased patients. The results are shown in Table 7 . Late effects were observed in 70/834 (8.4%) patients, of whom 17 had at least two late effects. Hepatitis and short stature were most commonly reported, followed by secondary malignancy, disturbed neurocognitive function, gonadal dysfunction and cardiomyopathy. There were no cases of osteoporosis or osteopenia. More than half the patients with short stature, leukoencephalopathy or visual disturbance received CRT.
Since late adverse effects are closely correlated with cumulative doses of cytotoxic drugs used in treatment protocols, we highlighted such cumulative doses of cytotoxic drugs and antimetabolites in each protocol (Table 8 ). In ALL811, CPM and DOX were used only for the HR protocols. In ALL841, CPM was used for only HR, but DOX was used for the HR and I841C protocols. In ALL874, CPM and anthracycline were used, as in ALL841. In ALL911, CPM was used for the IR and HR protocols and anthracycline was used for all the protocols, including SR patients. Consequently, cumulative doses of anthracycline exceeded 400 mg/m 2 in nine protocols (HR811B, IR841C, HR841B, IR874A and IR874B and 911LR/IR/HR/HHR) and Table 6 Life- ) was given orally every 6 h for a total seven doses. Rescue begins 36 h from the start of MTX infusion.
Long-term outcomes of children with acute lymphoblastic leukemia M Tsurusawa et al cumulative doses of CPA exceeded 4 g/m 2 in two protocols (HR811B and HR851B).
Discussion
Our results reveal that the cure rate has gradually increased from 55% with ALL811 to 70% with ALL911 over an observation period of 15 years, while toxic death rates during remission were below 1% in all protocols except ALL911. These results are favorably comparable to those from large pediatric ALL trials by other study groups, and reflect the effectiveness of risk-directed therapy and improvements in supportive care of children with ALL. [2] [3] [4] Improvement of outcome in each protocol study seems to be attributable to their respective aims. As shown in Table 4 , better outcome in ALL841 as compared with that in the ALL811 is partly explained by a decrease in isolate testicular relapse. This might be the result of the cyclic schedule of intermediatedose MTX in maintenance therapy. Improvement in ALL874 as compared with ALL841 was mainly due to a decrease in isolated CNS relapse. This was achieved by the CRT regimen for HR patients and extended intrathecal treatment for LR patients. The better survival rates in ALL911 as compared with ALL874 were mainly due to improved outcomes of the HR patients. The intensified chemotherapy of this protocol decreased the incidence of bone marrow relapse, although therapy-related death during remission increased to 4%. More importantly, as shown in Tables 5a-5d , outcomes of patients with high (50-99 Â 10 9 /l) WBC counts in ALL874 and ALL911 were markedly improved in comparison with those in the ALL811 and ALL841 studies. This is probably due to employment of consolidation therapy (CCM regimen) and reinduction therapy.
14 Another major interest in our studies is a unique intermittent cyclic regimen for maintenance chemotherapy. In the ALL811 study, we showed that intermittent cyclic administration of intermediate-dose MTX (225 mg/m 2 , intravenous) alternating biweekly 6MP (170 mg/day, orally for 5 days) was more effective than conventional administration of low-dose MTX (20 mg/m 2 /week, orally) and 6MP (50 mg/m 2 , orally, every day). 7 As a result of these data, intermittent cyclic administration of MTX and 6MP has become a standard regimen of maintenance chemotherapy in JCCLSG ALL protocols.
CNS protective chemotherapy without CRT for treatment of non-HR patients with ALL has been widely accepted. [15] [16] [17] [18] [19] In our study, the LR patients of L874B and L911 who received HDMTX therapy as CNS prophylaxis showed 7-9% cumulative incidence of isolated CNS relapse. However, BFM-based intensive chemotherapy using extended intrathecal chemotherapy has reported lower than 5% incidence of CNS relapse. 15, [19] [20] [21] Similar results are seen in the I911 protocol, where an extended triple inrathecal MTX regimen with intensive systemic therapy achieved a 2% cumulative incidence of CNS relapse in the IR patients. Thus, it is likely that systemic intravenous infusions of HDMTX could not be substituted for intrathecal injections of MTX in the maintenance therapy for CNS protection. This is also supported by the results of meta-analysis of CNS-directed therapy, which show that radiotherapy can be replaced by long-term intrathecal therapy but not by intravenous MTX. 22 Whether CRT can be excluded from preventive therapy for HR patients is still subject to controversy. In ALL851, we employed CNS chemoprophylaxis without CRT for the HR patients, but failed to prevent CNS relapse. 8 Since high incidence of CNS relapse is associated with high initial WBC count and T-cell phenotype, 23 ,24 development of a new strategy for these subgroups could overcome this difficult matter. In fact, a recent report from the Memphis group has shown that complete omission of prophylactic CRT without compromising OS can be achieved by using risk-adjusted chemotherapy based on minimal residual disease levels and pharmacogenetics. 25 In the ALL841-911 studies, the incidence of isolated testicular relapse was 7 of 278 relapses (2.5%), which was considerably lower than the general rate of about 10%. 26 The cyclic schedule of MTX at an intermediate dose in our maintenance therapy may contribute to prevention of relapse in sanctuary sites, especially in the testes.
Development of curative therapy for pediatric ALL has produced a large population of childhood cancer survivors who face increased risk of a variety of health problems resulting from their cancer or its treatment. In particular, secondary malignancy by alkylating agents and anthracycline cardiotoxicity are the most serious late events in pediatric cancer treatment. 27, 28 Fortunately, the incidences of secondary malignancies and cardiotoxicity were relatively small in our ALL studies. Although pirarubicin was chosen as an anthracyclin drug with less cardiotoxicity than DOX, it is unclear whether pirarubicin could reduce the incidence of cardiotoxicity without jeopardizing the overall outcome. 29, 30 In fact, our observation period with a median of 13 years (range 8-22 years) after diagnosis is too short to estimate the true incidence of late adverse effects, because excess mortality continues at least as long as 25-30 years after treatment, for cancer survivors. 27 Therefore, establishment of a long-term, follow-up care system based on collaboration between clinical and laboratory investigators is our most urgent issue. 31, 32 
